Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis

Overview

Journal Ann Lab Med

Specialty Pathology

Date 2013 Mar 14

PMID 23483759

Citations 2

Authors

Sang Hyuk Park

Sollip Kim

Chan-Jeoung Park

Seongsoo Jang

Hyun-Sook Chi

Kyung-Nam Koh

Ho Joon Im

Jong Jin Seo

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy.

Methods: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy.

Results: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P=0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P=0.852).

Conclusions: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.

Citing Articles

amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

Yue Z, Huang C, Gao C, Xing T, Liu S, Li X Cancer Cell Int. 2017; 17:43.

PMID: 28367105 PMC: 5374581. DOI: 10.1186/s12935-017-0412-z.

Morphologic alteration of metastatic neuroblastic tumor in bone marrow after chemotherapy.

Bae G, Suh Y, Sung K, Kim J Korean J Pathol. 2013; 47(5):433-42.

PMID: 24255631 PMC: 3830990. DOI: 10.4132/KoreanJPathol.2013.47.5.433.

References

Bagatell R, Rumcheva P, London W, Cohn S, Look A, Brodeur G . Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005; 23(34):8819-27. DOI: 10.1200/JCO.2004.00.2931. View

Ogita S, Tokiwa K, Arizono N, Takahashi T . Neuroblastoma: incomplete differentiation on the way to maturation or morphological alteration resembling maturity?. Oncology. 1988; 45(3):148-52. DOI: 10.1159/000226552. View

Reynolds C, Matthay K, Villablanca J, Maurer B . Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003; 197(1-2):185-92. DOI: 10.1016/s0304-3835(03)00108-3. View

Howman-Giles R, Shaw P, Uren R, Chung D . Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007; 37(4):286-302. DOI: 10.1053/j.semnuclmed.2007.02.009. View

Brodeur G, Seeger R, Barrett A, Berthold F, Castleberry R, DAngio G . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988; 6(12):1874-81. DOI: 10.1200/JCO.1988.6.12.1874. View

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999; 86(2):349-63. View

Nakagawara A, Ikeda K, Tasaka H . Dopaminergic neuroblastoma as a poor prognostic subgroup. J Pediatr Surg. 1988; 23(4):346-9. DOI: 10.1016/s0022-3468(88)80204-5. View

Lonergan G, Schwab C, Suarez E, Carlson C . Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002; 22(4):911-34. DOI: 10.1148/radiographics.22.4.g02jl15911. View

10.

Schmidt M, Lukens J, Seeger R, Brodeur G, Shimada H, Gerbing R . Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol. 2000; 18(6):1260-8. DOI: 10.1200/JCO.2000.18.6.1260. View

11.

Rozmus J, Langer M, Murphy J, Dix D . Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. J Pediatr Hematol Oncol. 2011; 34(2):151-3. DOI: 10.1097/MPH.0b013e318221ca82. View

12.

Ben Arush M, Ben Itzhak O, Yossilevski G, El Hasid R, Postovsky S, Israel O . Neuroblastoma maturation by [(131)I] metaiodobenzylguanidine in chemoresistant neuroblastoma. Med Pediatr Oncol. 1999; 33(4):418-9. DOI: 10.1002/(sici)1096-911x(199910)33:4<418::aid-mpo18>3.0.co;2-9. View

13.

Iwanaka T, Yamamoto K, Ogawa Y, Arai M, Ito M, Kishimoto H . Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg. 2001; 36(11):1633-6. DOI: 10.1053/jpsu.2001.27935. View

14.

Eklof O, Sandstedt B, Thonell S, AHSTROM L . Spontaneous regression of stage IV neuroblastoma. Acta Paediatr Scand. 1983; 72(3):473-6. DOI: 10.1111/j.1651-2227.1983.tb09752.x. View

15.

CALVO W, Forteza-Vila J . Schwann cells of the bone marrow. Blood. 1970; 36(2):180-8. View

16.

Candito M, Thyss A, Albertini M, Deville A, Politano S, Mariani R . Methylated catecholamine metabolites for diagnosis of neuroblastoma. Med Pediatr Oncol. 1992; 20(3):215-20. DOI: 10.1002/mpo.2950200306. View

17.

Haas D, Ablin A, Miller C, Zoger S, Matthay K . Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer. 1988; 62(4):818-25. DOI: 10.1002/1097-0142(19880815)62:4<818::aid-cncr2820620430>3.0.co;2-k. View

18.

McLaughlin J, Urich H . Maturing neuroblastoma and ganglioneuroblastoma: a study of four cases with long survival. J Pathol. 1977; 121(1):19-26. DOI: 10.1002/path.1711210104. View

19.

Peuchmaur M, DAmore E, Joshi V, Hata J, Roald B, Dehner L . Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003; 98(10):2274-81. DOI: 10.1002/cncr.11773. View

20.

Tornoczky T, Semjen D, Shimada H, Ambros I . Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. Pathol Oncol Res. 2007; 13(4):269-75. DOI: 10.1007/BF02940304. View